{
    "clinical_study": {
        "@rank": "112540", 
        "acronym": "DAISS", 
        "arm_group": [
            {
                "arm_group_label": "Experimental A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Experimental B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial will investigate the relationship of sleep, daytime performance and nocturia in\n      patients treated with Desmopressin or placebo. Male and Female patients will be administered\n      Desmopressin or Placebo every day for 3 months."
        }, 
        "brief_title": "Daytime Impact Sleep Study", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nocturia", 
        "condition_browse": {
            "mesh_term": "Nocturia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 2 night time voids per night\n\n          -  Habitual sleep of  6-9.5 hours per night\n\n          -  Experiencing symptoms of Nocturia greater than 6 months\n\n        Exclusion Criteria:\n\n          -  Greater than 10 night time voids\n\n          -  History of sleep apnoea and PLMS (Periodic Limb Movements of Sleep)\n\n          -  Other sleep disorders\n\n          -  Signs or symptoms of: Bladder outlet obstruction, severe lower urinary tract symptoms\n             (LUTS), interstitial cystitis, moderate to severe overactive bladder (OAB), moderate\n             to severe as judged by the investigator stress urinary incontinence\n\n          -  Urological malignancies\n\n          -  Neurogenic detrusor over activity (e.g. Parkinson, spinal cord damage, etc.)\n\n          -  Central or nephrogenic diabetes insipidus\n\n          -  Habitual or psychogenic polydipsia (fluid intake resulting in a urine production\n             exceeding 40ml/Kg/24hrs)\n\n          -  Syndrome of inappropriate antidiuretic hormone (SIADH)\n\n          -  Cardiac failure evidence based on physical examination, cardiac medical history and\n             electrocardiogram (ECG) output\n\n          -  Uncontrolled hypertension\n\n          -  Uncontrolled diabetes mellitus\n\n          -  Hyponatraemia with sodium <135 mmol/L\n\n          -  Renal insufficiency\n\n          -  Known or suspected clinically significant hepatic and/or biliary diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779466", 
            "org_study_id": "000088", 
            "secondary_id": "2012-004388-34"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Experimental A", 
                    "Experimental B"
                ], 
                "intervention_name": "Desmopressin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo (not active)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Deamino Arginine Vasopressin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Surrey", 
                    "country": "United Kingdom"
                }, 
                "name": "Surrey Clinical Research Centre"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated With Desmopressin Orally Disintegrating Tablets as Compared to Placebo", 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "As measured by voiding diary", 
                "measure": "Mean number of nocturnal voids", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "i.e. time in minutes of epochs scored as wake from sleep onset latency until lights on. Measured by Polysomnography", 
                "measure": "Wake after sleep onset", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Daytime performance", 
                "measure": "Daytime sleepiness score as measured by Karolinska Sleepiness Scale and Epworth Sleepiness Scale", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "As measured by voiding diary", 
                "measure": "Mean time to first void", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Sleep efficiency equals total sleep time divided by total recording time multiplied by 100. Measured by Polysomnography", 
                "measure": "Sleep efficiency", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Measured by Polysomnography", 
                "measure": "Sleep stage N1, N2, N3, (sleep stages in NREM (non-rapid eye movement) and REM (rapid eye movement) as a percentage of total sleep time", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Measured by Polysomnography", 
                "measure": "Number of awakenings due to nocturia", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Measured by Polysomnography", 
                "measure": "Latency to slow-wave sleep", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Measured by Actigraphy", 
                "measure": "Wake after sleep onset (WASO) i.e total minutes of wakefulness recorded after sleep onset", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Measured by Actigraphy", 
                "measure": "Percent of sleep", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Measured by Actigraphy", 
                "measure": "Number of awakenings due to nocturia", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "description": "Daytime performance", 
                "measure": "Quality of life score measured by EQ-5D-5L", 
                "safety_issue": "No", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "measure": "Safety - incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 month and 3 months"
            }, 
            {
                "measure": "Safety - clinically significant changes in lab values", 
                "safety_issue": "Yes", 
                "time_frame": "1 week and 3 months"
            }, 
            {
                "measure": "Safety - clinically significant changes in vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "1 week, 1 month and 3 months"
            }, 
            {
                "measure": "Safety - clinically significant changes in physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779466"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Terminated due to lack of eligible patients"
    }
}